Drug Trial Radar · NCT06011200
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Sep 16, 2023
Primary completion
Dec 11, 2023
Study completion May 11, 2024
Sponsor
- Lead sponsor
- CanSino Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes local infection and can cross the mucosal barrier to cause invasive bacteremia or epidemic meningococcal meningitis, meningococcus can often cause serious disease epidemics worldwide, the main clinical features of its infection are fever, rash and meningitis, the most common clinical manifestation is acute bacterial meningitis.
Conditions
- Epidemic Meningitis
Interventions
MCV4Biological
1 dose of MCV4 on Day 0
MSPV4Biological
1 dose of MSPV4 on Day 0
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean titers (GMT) of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunizationTime frame: 30 days after immunization
- Positive conversion rates of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunizationTime frame: 30 days after immunization
- Incidence of adverse reactions within 30 minutes after immunization in all subjectsTime frame: Within 30 minutes after immunization
- Incidence of adverse reactions/events within 7 days of immunization for all subjectsTime frame: Within 7 days after immunization
- Incidence of adverse reactions/events within 30 days of exemption for all subjectsTime frame: Within 30 days of exemption
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanyang County Center for Disease Prevention and Control
Shanyang, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.